Skip to main content
HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Cancer liver

Team Develops Potential New Approach to Stop Cancer Metastasis

NCATS scientists collaborated with NCI and Northwestern University researchers to identify a new compound that blocks the spread of several types of cancer in animal models.


Work with Us

BrIDGs forms partnerships with researchers from academia, nonprofit organizations and pharmaceutical and biotechnology companies to complete pre-clinical development for promising therapeutic candidates. Learn more and contact BrIDGs.

Bridging Interventional Development Gaps (BrIDGs)

The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage pre-clinical development toward an Investigational New Drug (IND) application and clinical testing. Learn more.

Find NCATS Programs & InitiativesAccess NCATS Expertise & Resources

About BrIDGs

Find out more about the BrIDGs program and its role in advancing new therapeutics.

Scientific Capabilities

BrIDGs offers state-of-the-art expertise and resources for pre-clinical development.

BrIDGs Projects

Explore active and completed pre-clinical development projects supported by BrIDGs.

Thinking about applying?

Review information for applicants.

Why BrIDGs Matters

As of fall 2015, BrIDGs has generated data to support 18 IND applications that have been cleared by the Food and Drug Administration and one clinical trial application cleared by Health Canada. A total of 14 projects have been evaluated in clinical trials. Five BrIDGs-supported agents have been evaluated in Phase II human clinical trials, in which researchers give an experimental therapy to a group of patients to evaluate the effectiveness and safety of a treatment. Third-party organizations have licensed or invested in 10 agents during or after their development by BrIDGs. Learn more about BrIDGs projects.